Drug Discovery

MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem cell therapy for moderate to severe knee osteoarthritis, in Japan.

Harbour BioMed and BMS sign multi-specific antibody collab

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement focused on multi-specific antibody discovery and development.

INCOG reveals $200m injectable drug expansion in Indiana

Contract development and manufacturing organisation (CDMO) INCOG BioPharma Services has announced injectable drug manufacturing expansion at its Fishers facility in the US state of Indiana, with an investment of around $200m.

LEO Pharma applies to EMA to expand Anzupgo use to adolescents

LEO Pharma has submitted an application to the European Medicines Agency (EMA) seeking to expand the label for Anzupgo (delgocitinib) cream to include adolescents aged from 12 to 17 with moderate to severe chronic hand eczema (CHE) in the European Union (EU).

SK Capital Partners supports Swixx BioPharma’s global expansion

US-based private investment company SK Capital Partners’ affiliate has agreed to invest in Swixx BioPharma to support the latter’s next stage of growth and international expansion.

FDA approves Acadia’s Daybue Stix for Rett syndrome

The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and preservative-free powder formulation of trofinetide, for oral solution, to treat Rett syndrome.

Sobi buys Arthrosi to expand gout treatment pipeline

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that will expand Sobi’s presence in the gout treatment market.

Boehringer’s Jascayd gains China’s NMPA approval for PPF

China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF).

Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.